Boardroom Alpha
Boardroom Alpha
DOCU · Current Report (Form 8-K) · Filed March 6, 2026

Docusign Inc — Current Report (Form 8-K)

Form
8-K
Filed
March 6, 2026
Period
Mar 5, 2026
Ticker
DOCU
Accession
0001261333-26-000006
Boardroom Alpha · Filing insights

Docusign appoints Brian Roberts to fill a board vacancy as an independent Class I director, term through 2028.

About Docusign Inc
Market cap
$10.7B
1Y TSR
−38.7%
3Y TSR
−3.4%
Board grade
C-
Sector
Technology
CEO
Allan C Thygesen
Last annual meeting: Jun 1, 2026 · View full Docusign Inc profile →
docu-20260305

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________

FORM 8-K
______________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2026
Commission File Number: 001-38465
______________________________________
DOCUSIGN, INC.
(Exact name of registrant as specified in its charter)
______________________________________
Delaware91-2183967
(State or Other Jurisdiction of Incorporation)(I.R.S. Employer Identification Number)
221 Main St.Suite 800San FranciscoCalifornia94105
(Address of Principal Executive Offices) (Zip Code)

(415) 489-4940
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.0001 per shareDOCUThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

Following the recommendation of Docusign, Inc.’s (the “Company”) Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Brian Roberts to fill an existing vacancy on the Board to serve as a director of the Company, effective March 5, 2026. Mr. Roberts will serve as a Class I director whose term will expire at the Company’s 2028 Annual Meeting of Stockholders, which is the next stockholder meeting at which Class I directors will be elected, and until Mr. Roberts’s successor shall have been duly elected and qualified, or until Mr. Roberts’s earlier death, resignation, disqualification or removal. The Board determined that Mr. Roberts qualifies as an independent director pursuant to the Securities Act of 1933, as amended, and the listing standards of the Nasdaq Stock Market.

There is no arrangement or understanding between Mr. Roberts and any other person pursuant to which Mr. Roberts was selected as a director. Mr. Roberts has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Roberts will receive compensation for his service as a member of the Board in accordance with the Company’s Amended and Restated Director Compensation Program, which is attached as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on September 7, 2023.

Mr. Roberts has also entered into the Company’s standard form of indemnity agreement, which is attached as Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on December 3, 2020.


Item 9.01     Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 6, 2026
DOCUSIGN, INC.
By:/s/ James P. Shaughnessy
James P. Shaughnessy
Chief Legal Officer


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Docusign Inc (DOCU)

Reference

Frequently asked questions

When did Docusign Inc file this 8-K?
Docusign Inc (DOCU) filed this Current Report (Form 8-K) with the SEC on March 6, 2026. The accession number assigned by EDGAR is 0001261333-26-000006.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Docusign appoints Brian Roberts to fill a board vacancy as an independent Class I director, term through 2028. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Docusign Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Docusign Inc has filed under CIK 1261333, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer